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Abstract Zinc exhibits antidepressant-like activity in
preclinical tests/models. Moreover, zinc homeostasis is
implicated in the pathophysiology of affective disorders. The
aim of the present study was to examine the effect of chronic
zinc, citalopram and imipramine intraperitoneal adminis-
tration on the presynaptic and extracellular zinc concentra-
tion in the rat prefrontal cortex and hippocampus. We used
two methods: zinc–selenium histochemistry (which images
the pool of presynaptic-vesicle zinc) and anodic stripping
voltammetry (ASV) for zinc determination in microdialysate
(which assays the extracellular zinc concentration). We
report that chronic (149) zinc (hydroaspartate, 10 and
65 mg/kg) and citalopram (20 mg/kg) administration
increased the pool of presynaptic zinc (by 34, 50 and 37%,
respectively) in the rat prefrontal cortex. The 21% increase
induced by imipramine (20 mg/kg) was marginally signifi-
cant. Likewise, zinc (hydroaspartate, 65 mg/kg), citalopram
and imipramine increased the extracellular zinc (although
with a different pattern: time point, area under the curve and/
or basal level) in this brain region. Furthermore, zinc induced
an increase in presynaptic (by 65%) and extracellular zinc
(by 90%) in the hippocampus, while both citalopram and
imipramine did not. These results indicate that all of the
treatments increase presynaptic/extracellular zinc concen-
trations in the rat prefrontal cortex, which may then con-
tribute to their antidepressant mechanisms. Alterations
induced by zinc (but not antidepressants) administration in
the hippocampus may be related to specific zinc mecha-
nisms. All the data (previous and present) on the effect of
antidepressant treatments on the presynaptic/extracellular
zinc concentrations suggest the involvement of this biometal
presynaptic/synaptic homeostasis in the antidepressant
mechanism(s).
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Introduction
Zinc is the second most abundant trace metal (after iron) in
mammalian tissues, and it is an essential element for
growth, development, DNA synthesis, immunity and other
important cellular processes (Takeda 2000). Besides, this
trace element acts as a cellular signaling molecule and is
present in many regions of the mammalian central nervous
system (CNS), particularly in the cerebral cortex and hip-
pocampus (Frederickson et al. 2005).
Less than 5% of the total amount of zinc in the brain is
located inside presynaptic vesicles in zinc-containing
neuron terminals. This pool of zinc can be selectively
stained by several histochemical procedures that make it
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then available to histological and histochemical studies.
The majority of vesicular zinc is found within glutama-
tergic neurons, although not all of the glutamatergic neu-
rons contain zinc (Frederickson and Bush 2001; Slomianka
1992). Presynaptic zinc is released in an activity-dependent
manner, diffuses across the synaptic cleft and proceeds to
have some effect on the postsynaptic neuron. Zinc is an
important modulator of inhibitory and excitatory synaptic
transmissions. It has been shown to modulate the action of
multiple receptors and channels, enhancing AMPA (GluR3
subunit) and ATP-sensitive potassium (KATP) channel
activity and inhibiting NMDA, GABAA and voltage-
dependent channel responses (Bancila et al. 2004; Harrison
and Gibbons 1994; Smart et al. 1994).
It has been assumed that alteration in zinc homeostasis
is associated with growth disturbances in children, immune
deficiency and behavioral disturbances, such as taste and
smell acuity, dysphoria, anorexia, impaired learning and
cognitive function, besides some neurological disorders
(e.g. epilepsy, Alzheimer’s disease) (Frederickson et al.
2005; Takeda et al. 2003). Recent experimental and clinical
observations have suggested that zinc is involved in the
psychopathology and therapy of depression (see Szewczyk
et al. 2008 for review). Several reports have revealed lower
serum zinc concentration in patients suffering from
depression (Maes et al. 1994, 1997, 1999; Nowak et al.
1999), which was then normalized after successful anti-
depressant therapy (Maes et al. 1999; McLoughlin and
Hodge 1990; Schlegel-Zawadzka et al. 2000). Addition-
ally, our clinical study indicates the beneficial role of zinc
supplementation on antidepressant therapy in unipolar
depression (Nowak et al. 2003a), especially in drug-
resistant patients (Siwek et al. 2009).
Pre-clinical studies have shown that acute and repeated
zinc administration produces an antidepressant-like effect
in animal behavioral tests (tail suspension test, forced
swimming test; Kroczka et al. 2000, 2001; Rosa et al.
2003) and models of depression (chronic, mild and
unpredictable stress, olfactory bulbectomy; Cieslik et al.
2007; Cunha et al. 2008; Nowak et al. 2003c; Sowa-Kuc´ma
et al. 2008). Moreover, the co-administration of zinc and
antidepressants at ineffective doses exhibits an antide-
pressant-like effect (Kroczka et al. 2001; Szewczyk et al.
2002, 2009; Cieslik et al. 2007). On the other hand, zinc
deficiency induces depressive behavior and neurochemical
changes in rodents (Corniola et al. 2008; Tassabehji et al.
2008; Whittle et al. 2009).
All these data suggest possible antidepressant/adjunct
zinc activity in human depression. However, the mecha-
nism of zinc antidepressant action, at the cellular level, is
not clearly understood.
Since the mechanism of antidepressants is related to
adaptive changes induced by chronic treatment, in the
present study, we investigated the influence of chronic
zinc, imipramine and citalopram treatment on the presyn-
aptic (vesicular) and extracellular (synaptic) zinc level in
the rat prefrontal cortex and hippocampus. These brain
regions were chosen because preclinical and clinical stud-
ies have revealed their importance in depression [e.g.
(Rajkowska and Miguel-Hidalgo 2007; Drevets et al. 2008;
Lorenzetti et al. 2009)]. We used the zinc–selenium
method (which visualizes the vesicular zinc) and anodic
stripping voltammetric zinc detection in brain microdialy-
sates (which assays extracellular zinc). The dose/treatment
schedule of zinc was previously examined and was effec-
tive in behavioral and biochemical experiments (Kroczka
et al. 2000, 2001; Nowak et al. 2003c, 2004; Rosa et al.
2003; Sowa-Kuc´ma et al. 2008).
Materials and methods
Animals
The experiments were carried out on male Wistar rats
(280–320 g). The animals were kept under a 12:12 h light–
dark cycle with free access to food and water. The exper-
imental group consisted of four to six animals. Zinc
hydroaspartate (Farmapol, Poznan, Poland) at a dose of
10 mg/kg (1.8 mg of zinc/kg) or 65 mg/kg (11.3 mg
of zinc/kg), imipramine (Sigma, Germany) at a dose of
20 mg/kg and citalopram (Lundbeck, Denmark) at a dose
of 20 mg/kg or vehicle (0.9% sodium chloride, control
rats) were administered intraperitoneally (i.p.), once daily
for 14 days. All procedures were conducted in compliance
with the National Institutes of Health Animal Care and Use
Committee guidelines, and were approved by the Ethics
Committee of the Institute of Pharmacology, PAS,
Krakow.
Synaptic zinc visualization
For histochemical detection of presynaptic (histochemi-
cally reactive, vesicular) zinc, we applied the zinc–
selenium method (Timm’s staining) described by Danscher
(1982) with modifications described by Czupryn and
Skangiel-Kramska (2003). In this method, the presynaptic
pool of zinc is visualized with silver salt enhancement after
the application of exogenous selenite. Sodium selenite was
administered intraperitoneally at a dose of 15 mg/kg, 24 h
after the last treatment of zinc hydroaspartate, imipramine
and citalopram. The rats were deeply anesthetized with
vetbutal (0.7 mg/kg) 1 h after sodium selenite administra-
tion and perfused transcardially with 0.1 M So¨rensen’s
buffer (pH 7.4) for 7 min. After perfusion the brains were
quickly removed, frozen in cold heptane (-70C). Thick
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coronal sections (20 lm) were cut in a cryostat,
thaw-mounted onto gelatin/chrome-alum-coated glass
slides and stored at -70C until histochemical processing.
The brain sections were allowed to dry at room tem-
perature, hydrated, fixed in a descending series of ethanol
(15 min in 95%, 2 min both in 70 and 50%), dipped in
water and finally in 0.5% gelatin solution. Then the slides
were immersed in fresh developing solution (60 ml of 40%
gum arabic, 10 ml of 2 M sodium citrate buffer (pH 3.5),
15 ml of 0.5 M hydroquinone and 15 ml of 37 mM silver
lactate) and incubated in a dark room at 26C for 140 min.
The developing solution was then poured off, and the gum
arabic was removed from the slices by washing in running
tap water (40C) for 20 min, followed by rinsing twice for
2 min in deionized water. It was postfixed in 70% ethanol
for 30 min and dehydrated in an ascending ethanol
series. Finally, the sections were cleared with xylene and
coverslipped using Permount.
Analysis of sections and semiquantitative
measurements
The coronal sections of the dorsal hippocampus and frontal
cortex were examined under a light microscope (Optiphot,
Nikon). The optical density measurements were obtained
using an image analysis system (MCID M4; Imaging
Research Inc. Ont., Canada). The staining intensity was
examined in 15–20 sections of each rat at levels -3.14 to
-3.8 (in the hippocampus) and 3.5–2.6 (in the prefrontal
cortex) in relation to bregma, according to the Paxinos and
Watson (1998) stereotaxic coordinates. Both the right and
left frontal cortices and hippocampi were analyzed. The
stratum moleculare fascia dentate of the DG and the corpus
callosum (the regions consistently showing low staining
levels) were taken as reference structures in each section in
the hippocampus and prefrontal cortex, respectively. The
relative optical density (ROD) values for each structure
was determined by estimation of mean values divided by
the ROD obtained in the reference area.
In vivo microdialysis
One day before the experiment, the rats were anesthetized
with ketamine (75 mg/kg i.m.) and xylazine (10 mg/kg
i.m.) and placed into a stereotaxic apparatus (David Kopf
Instruments, Tujunga, CA, USA). The scalp was retracted
and holes drilled through the skull for insertion of the
vertical microdialysis probe into the prefrontal cortex
(2.7 mm anterior from the bregma, 0.6 mm lateral from the
sagittal suture and -5.5 mm ventral from the dural surface)
or hippocampus (-3.8 mm anterior from the bregma,
3.4 mm lateral from the sagittal suture and -4.0 mm
ventral from the dural surface) (Paxinos and Watson 1998).
Microdialysis probes were constructed by inserting two
fused silica tubes (30 and 35 mm long, 150 lm outer
diameter (o.d.); Polymicro Technologies Inc., Phoenix, AZ,
USA) into a microdialysis fiber (220 lm o.d., AN69,
Hospal, Bologna, Italy). The tube assembly was placed in a
stainless steel cannula (22 gauge, 10 mm) forming the shaft
of the probe. Portions of the inlet and outlet tubes were
individually placed inside polyethylene PE-10 tubing and
glued for protection. The free end of the dialysis fiber was
sealed, and 4 mm of the exposed length or 3 mm in the
hippocampus was used for dialysis in the prefrontal cortex.
One day after surgery and probe implantation, the inlet
of the dialysis probes was connected to a syringe pump
(BAS, IN, USA), which delivered an artificial cerebrospi-
nal fluid (aCSF) composed of (in mM) NaCl 145, KCl 2.7,
MgCl2 1.0, CaCl2 1.2, pH = 7.4, at a flow of 1.5 ll/min.
After 3 h of this washing period, when the extracellular
level of zinc became stable, two baseline samples were
collected every 40 min from freely moving animals. Next,
the last doses of zinc hydroaspartate, imipramine or
citalopram were i.p. injected into the animals and the
consequent dialysate fractions were collected every 40 min
for 160 min. At the end of the experiment, the rats were
killed and their brains were histologically examined to
validate the correct probe placement.
Extracellular zinc determination
For detection of extracellular zinc concentration in brain
microdialysates, we used differential pulse anodic stripping
voltammetry (DP ASV, described in detail in Opoka et al.
2008).
Brain microdialysate samples were acidified with nitric
acid immediately after collection by addition of 1 ll HNO3
(conc.) to each 30 ll of the sample. The pretreatment,
intended to destroy organic compounds (complexants and
organic surfactants), followed the wet washing method
used in the DP ASV determination of zinc ions in micro-
dialysates. Then, samples were transferred directly into a
miniature quartz tube and digested by UV irradiation for
2 h. The quartz tubes were then left to cool to room tem-
perature. Aliquots of 20 ll of this solution were introduced
into the electrochemical cell containing 2 ml of the
supporting electrolyte.
For all the voltammetric measurements, a multipurpose
Electrochemical Analyzer M161 with and electrode stand
M164 (both MTM-ANKO, Poland) was used. The stripping
was performed in the differential pulse (DP) mode. As much
as 2 ml of 0.05 M KNO3 was added in the electrochemical
cell as a blank and the solution was purged with argon of
99.995% purity for at least 5–7 min. The preconcentration
step was carried out from the stirred solution for a period of
tacc = 20 s at Eaac = -1.05 V versus Ag/AgCl, at a fresh
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mercury drop. After a rest period of 5 s, the differential pulse
voltammogram was recorded in the anodic direction from
-1.05 to -0.8 V with a potential scan rate of 25 mV/s and
pulse amplitude of -50 mV. The voltammogram for the
blank solution demonstrates electrochemical cell and sup-
ports electrolyte purity. Then, 20 ll of sample solution was
added to the cell while maintaining an argon atmosphere
over the solution and the differential pulse voltammograms
were recorded. The quantitative determinations of zinc ions
were performed using the standard additions method (three
concentrations). Three curves were recorded and averaged
for each of the concentrations. All of the samples were
measured under the same conditions.
Data analysis
The results of the experiments were expressed as the
means ± SEM. The obtained data were evaluated by one-
way or repeated measures of ANOVA followed by Dunnett’s
or Tukey’s post hoc test, respectively, and the Student’s
t test. Data were deemed significant when P \ 0.05.
Results
Microscopic analysis of synaptic zinc
Effect of chronic treatment with zinc hydroaspartate,
imipramine and citalopram on the presynaptic zinc level
in the rat prefrontal cortex
Densitometric analysis of the staining intensity of presyn-
aptic (histochemically reactive, vesicular) zinc in the rat’s
prefrontal cortex showed a significant increase by zinc
hydroaspartate or citalopram administration (Fig. 1a, b).
ANOVA revealed F(4,32) = 4.475, P = 0.0064. The
higher level (50% of increase; P \ 0.01) of zinc staining
was observed after a treatment of zinc hydroaspartate at a
dose of 65 mg/kg (*11.3 mg of zinc/kg). A small increase
(by 34%; P \ 0.05) compared to that in the control rats
was also recorded after the use of a lower dose of zinc
hydroaspartate (10 mg/kg; *1.8 mg of zinc/kg). A similar
effect (37% of increase; P \ 0.05) was noted after
citalopram administration. Moreover, imipramine treat-
ment caused a statistically marginal increase (by 21%,
P = 0.057) of staining intensity (Fig. 1a).
Effect of chronic treatment with zinc hydroaspartate,
imipramine and citalopram on the presynaptic zinc level
in the rat hippocampus
ANOVA revealed a significant effect of treatment on the
presynaptic concentration in the whole hippocampus
[ANOVA: F(3,22) = 7.35, P \ 0.01]. Post hoc testing
revealed that repeated zinc hydroaspartate treatment at a
dose of 10 mg/kg (*1.8 mg of zinc/kg; P \ 0.05)
increased synaptic zinc staining in the whole hippocampus
(Fig. 2).
Detailed measurement of relative optical density (ROD)
performed in the Ammon’s horn (CA) and dentate gyrus
(DG) area showed a significant increase (by 19 and 24%,
respectively) of synaptic zinc staining; ANOVA:
F(3,22) = 5.137, P = 0.0104 (CA area); F(3,22) = 9.227,
P = 0.008 (DG area). This effect was stronger (with a 65%
increase) after a higher dose of zinc (*11.3 mg of zinc/kg)
administration [Student’s t test: t(9) = 5.583, P = 0.0025
(CA area); t(9) = 2.837, P = 0.0364 (DG area);
t(9) = 5.310, P = 0.0032 (whole hippocampus)]. No
alterations in the distribution and intensity of zinc staining
were observed after imipramine and citalopram treatment
(Fig. 2).
Analysis of extracellular zinc concentration in brain
microdialysate samples
The effect of chronic treatment with zinc hydroaspartate,
imipramine and citalopram on the extracellular zinc
concentration in the rat prefrontal cortex
Chronic imipramine administration at a dose of 20 mg/kg
had no significant effect on the basal extracellular con-
centration of zinc in the prefrontal cortex (Table 1).
However, such chronic treatment with zinc hydroaspartate
(65 mg/kg; 11.3 mg of zinc/kg) or citalopram (20 mg/kg)
significantly (by 41%; P \ 0.05 or 36%; P \ 0.05,
respectively) increased the extracellular zinc level when
compared to the group treated with saline (Table 1). The
maximal effect was seen 40 min (188% of basal level;
P \ 0.001) or between 80 (187% of basal level; P \ 0.01)
and 120 min after the last doses of zinc hydroaspartate or
citalopram administration, respectively (Fig. 3a; repeated
measures ANOVA: F(3,23) = 10.893, P = 0.0002).
Imipramine and citalopram, while zinc does not, increase
the cumulative effect presented as an area under the curve
(AUC, Fig. 3b; repeated measures ANOVA: F(3,20) =
9.734, P = 0.0006).
The effect of chronic treatment with zinc hydroaspartate
and citalopram on extracellular zinc concentration
in the rat hippocampus
Chronic treatment with zinc hydroaspartate (65 mg/kg;
11.3 mg of zinc/kg) or citalopram (20 mg/kg) significantly
(by 38%; P \ 0.01 or 29%; P \ 0.05, respectively)
increased the basal extracellular zinc level when compared
with the group treated with saline (Table 1). The maximal
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effect was seen at 40 min (190% of basal level; P \ 0.05)
after the final doses of zinc hydroaspartate (Fig. 4a).
Citalopram induced no significant effect (Fig. 4a). Repe-
ated measures ANOVA: F(2,17) = 5.546, P = 0.0110.
None of the examined agents affected the area under the
curve measurement (AUC, Fig. 4b).
Discussion
Zinc is co-released with glutamate upon activity of the
presynaptic nerve terminals (Qian and Noebels 2005; Vogt
et al. 2000). Chronic antidepressant treatment modifies the
glutamatergic synapse, reducing its transmission by
0
1
2
3
Control Imipramine 20 mg/kg Citalopram 20 mg/kg
Zinc hydroaspartate 10 mg/kg Zinc hydroaspartate 65 mg/kg
*
**
*
Control IMI CIT Zn 10 Zn 65
Prefrontal CortexA
R
.O
.D
.
I
III
II
IV
B
Fig. 1 a The effect of chronic
(14 days) treatment with zinc
hydroaspartate, imipramine and
citalopram on presynaptic zinc
level in the rat prefrontal cortex
measured by the selenium
method. Values are expressed in
relative optical density (ROD)
as mean ± SEM of 15–20
sections from each of six rats
per group. *P \ 0.05,
**P \ 0.01 versus control
(Dunnett’s post hoc test).
b Photomicrographs
representing synaptic zinc
staining in the prefrontal
cortical sections from control (I,
III) and zinc hydroaspartate
(65 mg/kg) treated rats (II, IV).
Calibration bars in I and II,
500 lm; III and IV, 200 lm
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altering the glutamate NMDA receptors (Dybala et al.
2006; Mathie et al. 2006; Skolnick et al. 1996; Szewczyk
et al. 2001). The opposite of these alterations is what has
been proposed for depression (experimental models of
depression) (Garcia et al. 2009; Kos et al. 2006; Machado-
Vieira et al. 2009; Nowak et al. 2003b; Popik et al. 2008;
Zarate et al. 2006). Since the accumulated data demonstrate
the antidepressant/adjunct role of zinc in preclinical and
clinical reports (Nowak et al. 2003a; Siwek et al. 2009; see
Szewczyk et al. 2008 for review), one may suggest the
involvement of ‘‘endogenous’’ zinc in the mechanism of
antidepressant action. Actually, the presynaptic zinc
(vesicular, histochemically reactive) level is enhanced by
chronic electroconvulsive treatment (ECT) in the rat hip-
pocampus (Gombos et al. 1999; Lamont et al. 2001;
Vaidya et al. 1999). Moreover, our previous data demon-
strated that repeated administration of zinc increases this
particular pool of presynaptic zinc in the hippocampus
(Szewczyk et al. 2006). However, such an effect is not
demonstrated by chronic antidepressant drug treatment
(Lamont et al. 2001). The total hippocampal zinc level is
slightly increased by chronic treatment with imipramine or
citalopram and the same treatments slightly reduce it in the
neocortex of rats (Nowak and Schlegel-Zawadzka 1999).
Chronic ECT, on the other hand, robustly increases the
total zinc in both brain regions (Nowak and Schlegel-
Zawadzka 1999).
The present data focused our attention to the frontal
cortex. We demonstrated the increase in the presynaptic
zinc pool induced by chronic treatment with zinc, citalo-
pram and marginally by imipramine. Even more clearly,
the effect was demonstrated in the extracellular zinc pool.
All the examined treatments (zinc, citalopram, imipramine)
produced an increase (with a different pattern of the
dynamics of treatment-induced changes) in the extracel-
lular zinc pool, measured at the time points as an area
under the curve and/or basal level in the rat prefrontal
cortex. The differences in the pattern of changes may be
related to their differences in pharmacological mecha-
nisms. Citalopram is a very potent and specific serotonin
reuptake inhibitor, while imipramine is a serotonin/
noradrenaline reuptake inhibitor (Hyttel 1994). Thus, a
strong serotonin enhancing mechanism may be important
for the induction of an increase of presynaptic/extracellular
zinc, especially in view of the recent study which indicates
that the antidepressant-like activity of zinc depends on
serotonin transmission (Szewczyk et al. 2009). A very
rapid effect was noticed in the zinc treatment, a delayed but
pronounced one for citalopram and a weak effect with
imipramine. The basal level increased by zinc and citalo-
pram treatment may represent an increased, yet stable, high
concentration of zinc, which persistently interacts with
different targets within the synapse. It should be noted that
zinc is able to induce a transient increase in the extracel-
lular zinc pool in the frontal cortex even by a single
administration (Opoka et al. 2008).
It should be noticed that enhancement in the basal
extracellular zinc in the frontal cortex, induced by chronic
treatment with zinc and citalopram, is associated with an
enhancement in presynaptic zinc assayed at the same time
(24 h after the last administration).
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.
Fig. 2 The effect of chronic (14 days) treatment with zinc hydroas-
partate, imipramine and citalopram on the presynaptic zinc level in
the rat hippocampus measured by the selenium method. Values are
expressed in relative optical density (ROD) as mean ± SEM of 15–20
sections from all of the six rats per group. a Ammon’s horn (CA) area,
b dentate gyrus (DG) area, c whole hippocampus. The results of zinc
hydroaspartate at a dose of 65 mg/kg were calculated from the
detailed data published previously (Szewczyk et al. 2006). *P \ 0.05,
**P \ 0.01 versus control (Dunnett’s post hoc test or Student’s t test)
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Chronic treatment with zinc and citalopram increased
basal extracellular zinc in the hippocampus, while zinc
alone produced a parallel enhancement of the presynaptic
zinc pool in this structure (present data, Szewczyk et al.
2006). Thus, hippocampal presynaptic/extracellular
homeostasis is regulated, similar to that in the cortex, only
by zinc and not by citalopram treatment. The dynamics of
the changes in the extracellular Zn induced by chronic
treatment may represent a functionally operating synaptic
zinc interacting with a variety of receptors and channels
(Nakashima and Dyck 2009). Generally, citalopram’s
effect on presynaptic/extracellular zinc homeostasis is
greater than the one by imipramine. It might be that a
strong serotonergic component of the antidepressant
activity of citalopram and zinc [recently demonstrated by
(Cunha et al. 2008; Szewczyk et al. 2009)] has such an
effect on presynaptic/extracellular Zn, which warrants
future studies.
Table 1 Effect of chronic treatment with imipramine, citalopram or zinc on basal level of zinc in extracellular fluid measured in microdialysates
by anodic stripping voltammetry
Brain region Control Imipramine Citalopram Zinc
Prefrontal cortex 0.96 ± 0.061 1.16 ± 0.087 1.32 ± 0.067* 1.35 ± 0.126*
Hippocampus 0.95 ± 0.063 n.d. 1.23 ± 0.039* 1.31 ± 0.084**
Rats were treated with imipramine (20 mg/kg), citalopram (20 mg/kg) or zinc (hydroaspartate, 65 mg/kg) once a day for 14 days. Results are
expressed in lM as mean ± SEM of four to five rats per group. ANOVA: F(3,20) = 5.827, P = 0.0063 (prefrontal cortex); F(2,13) = 7.985,
P = 0.0008 (hippocampus)
n.d. not determined
* P \ 0.05, ** P \ 0.01 versus control (Dunnett’s post hoc test)
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Fig. 3 The effect of chronic (14 days) treatment with zinc hydroa-
spatate, imipramine and citalopram on extracellular concentration of
zinc in the rat prefrontal cortex measured in microdialysates by
anodic stripping voltammetry. a Time course of the effect. The last
administration is indicated by an arrow. b Area under the curve of
160 min collection time. Values are expressed as mean ± SEM,
n = 4–5 rats. *P \ 0.05, **P \ 0.01, ***P \ 0.001 versus basal
level or control group (Tukey’s post hoc test)
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Fig. 4 The effect of chronic (14 days) treatment with zinc hydroas-
partate and citalopram on extracellular concentration of zinc in the rat
hippocampus measured in microdialysates by anodic stripping
voltammetry. a Time course of the effect. The last administration is
indicated by an arrow. b Area under the curve of 160 min collection
time. Values are expressed as mean ± SEM, n = 4–5 rats. *P \ 0.05
versus basal level (Tukey’s post hoc test)
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Recently, we demonstrated the involvement of the
NMDA and AMPA glutamate receptors in the antidepres-
sant-like activity of zinc in the FST (Poleszak et al. 2008;
Szewczyk et al. 2010). The reduction in the immobility
time induced by zinc is abolished by activation of NMDA
receptor complex (by NMDA or D-serine) and by antago-
nism of the AMPA receptor (by NBQX) (Poleszak et al.
2008; Szewczyk et al. 2010). Moreover, the reduction in
the NMDA/AMPA reactivity induced by chronic antide-
pressants and zinc treatments is demonstrated by an elec-
trophysiological method (Bobula and Hess 2008). Our
recent data indicated that chronic zinc treatment induced
up-regulation of the 5-HT-1A and 5HT-2A serotonergic
and down-regulation of the glycine/NMDA glutamatergic
receptor, and enhances the BDNF mRNA and protein
expressions, which are similar to that induced by conven-
tional antidepressants (Cichy et al. 2009; Nowak et al.
2004; Paul and Skolnick 2003; Sowa-Kucma et al. 2008).
Our results potentially indicate that an increase in the
presynaptic/synaptic zinc concentration may be responsible
(at least in part) for the induction of these adaptive alter-
ations, which are involved in the antidepressant mechanism
(Szewczyk et al. 2008). In view of the recent paper of
Besser et al. (2009), synaptically released zinc may also
activate the metabotropic zinc-sensing receptors ZnR
(GPR39), specifically activated by zinc, besides the
receptors for the well-known neurotransmitters [e.g. glu-
tamate or serotonin (Nakashima and Dyck 2009)].
Accordingly, antidepressants induced the enhancement of
synaptically released (extracellular) zinc via ZnR-induced
enhancement of intracellular signal-regulated protein
kinase1/2 (ERK1/2) and Ca2?/calmodulin-activated pro-
tein kinase II (CaMKII), brain-derived neurotrophic factor
(BDNF) cascade may activate anti-apoptotic/neurogenesis
pathway(s) (Franco et al. 2008) involved in the antide-
pressant mechanism [e.g. see Covington et al. 2009;
Duman and Monteggia 2006 for review]. Now, we can
address the question of how chronic treatment with anti-
depressants increases the synaptic/extracellular zinc con-
centrations. We can speculate that antidepressants can
move zinc from the protein-bound pool to the vesicle pool,
then onto the extracellular, synaptic reactive pool, but this
of course remains to be proved.
These data open exciting avenues to the hypothesis that
the antidepressant mechanism relies on adaptive changes
evoked by an antidepressant-induced increase of zinc in the
synapse, and this notion should be examined in future
studies.
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